[THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].

Acute myeloid leukemia (AML) is a hematologic malignancy with great variability in the pathogenesis, clinical features and treatment outcomes. Advances in molecular research have greatly improved our understanding of the leukemogenesis in AML. In addition to the conventional risk factors molecular genetic alterations, such as mutations of NPM1, CEBPA, c-KIT, AML1/RUNX1, WT1, FLT3 and others, are also important prognostic factors in AML patients. Risk-adapted treatment may not only improve the prognosis, but also reduce the toxicity from the chemotherapy in patients with AML.